Literature DB >> 10415024

Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles.

M J Martínez-Lorenzo1, A Anel, S Gamen, I Monle n, P Lasierra, L Larrad, A Piñeiro, M A Alava, J Naval.   

Abstract

Activation-induced cell death is a process by which overactivated T cells are eliminated, thus preventing potential autoimmune attacks. Two known mediators of activation-induced cell death are Fas(CD95) ligand (FasL) and APO2 ligand (APO2L)/TNF-related apoptosis-inducing ligand (TRAIL). We show here that upon mitogenic stimulation, bioactive FasL and APO2L are released from the T cell leukemia Jurkat and from normal human T cell blasts as intact, nonproteolyzed proteins associated with a particulate, ultracentrifugable fraction. We have characterized this fraction as microvesicles of 100-200 nm in diameter. These microvesicles are released from Jurkat and T cell blasts shortly (</=1 h) after PHA stimulation, well before the cell enters apoptosis. FasL- and APO2L-containing vesicles are also present in supernatants from PHA-activated fresh human PBMC. These observations provide the basis for a new and efficient mechanism for the rapid induction of autocrine or paracrine cell death during immune regulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415024

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  84 in total

1.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism.

Authors:  Steven P O'Hara; Aaron J Small; Jeremy B Nelson; Andrew D Badley; Xian-Ming Chen; Gregory J Gores; Nicholas F Larusso
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

3.  Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.

Authors:  Rachel M Locklin; Ermanno Federici; Belen Espina; Philippa A Hulley; R Graham G Russell; Claire M Edwards
Journal:  Mol Cancer Ther       Date:  2007-12-07       Impact factor: 6.261

Review 4.  Post-translational modification and protein sorting to small extracellular vesicles including exosomes by ubiquitin and UBLs.

Authors:  Hiroshi Ageta; Kunihiro Tsuchida
Journal:  Cell Mol Life Sci       Date:  2019-07-30       Impact factor: 9.261

5.  Protein kinase D1/2 is involved in the maturation of multivesicular bodies and secretion of exosomes in T and B lymphocytes.

Authors:  C Mazzeo; V Calvo; R Alonso; I Mérida; M Izquierdo
Journal:  Cell Death Differ       Date:  2015-06-05       Impact factor: 15.828

6.  Assessment of differential gene expression patterns in human colon cancers.

Authors:  A Hernandez; F Smith; Q Wang; X Wang; B M Evers
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

7.  Testicular FasL is expressed by sperm cells.

Authors:  A D'Alessio; A Riccioli; P Lauretti; F Padula; B Muciaccia; P De Cesaris; A Filippini; S Nagata; E Ziparo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

8.  CD40L is transferred to antigen-presenting B cells during delivery of T-cell help.

Authors:  Jennifer L Gardell; David C Parker
Journal:  Eur J Immunol       Date:  2016-11-28       Impact factor: 5.532

Review 9.  Role of diacylglycerol kinases in T cell development and function.

Authors:  Sruti Krishna; Xiaoping Zhong
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

10.  Involvement of tumour necrosis factor-alpha-related apoptosis-inducing ligand in enhanced cytotoxicity of lipopolysaccharide-stimulated dendritic cells to activated T cells.

Authors:  Yizhi Yu; Shuxun Liu; Wenya Wang; Wengang Song; Minghui Zhang; Weiping Zhang; Zhihai Qin; Xuetao Cao
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.